Education
About Us
Working with TipRanks
Follow Us
Vaxil Bio Ltd (TSE:VXL)
:VXL
Total Valuation
Vaxil Bio has a market cap or net worth of C$547.92K. The enterprise value is C$99.92K.
Market CapC$547.92K
Enterprise ValueC$99.92K
Share Statistics
Vaxil Bio has 2,739,580 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,739,580
Owned by Insiders―
Owned by Institutions0.01%
Financial Efficiency
Vaxil Bio’s return on equity (ROE) is -0.25 and return on invested capital (ROIC) is -27.37%.
Return on Equity (ROE)-0.25
Return on Assets (ROA)-0.24
Return on Invested Capital (ROIC)-27.37%
Return on Capital Employed (ROCE)-0.27
Revenue Per Employee―
Profits Per Employee-10.00T>
Employee Count―
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Vaxil Bio is -157.76. Vaxil Bio’s PEG ratio is <0.01.
PE Ratio-157.76
PS Ratio0.00
PB Ratio0.77
Price to Fair Value39.22
Price to FCF-3.51
Price to Operating Cash Flow-3.51
PEG Ratio<0.01
Income Statement
In the last 12 months, Vaxil Bio had revenue of 0.00 and earned -178.00K in profits. Earnings per share was 0.00.
Revenue0.00
Gross Profit0.00
Operating Income-196.00K
Pretax Income-178.00K
Net Income-178.00K
EBITDA-178.00K
Earnings Per Share (EPS)0.00
Cash Flow
In the last 12 months, operating cash flow was -156.08K and capital expenditures 0.00, giving a free cash flow of -156.08K billion.
Operating Cash Flow-156.08K
Free Cash Flow-156.08K
Free Cash Flow per Share-0.06
Dividends & Yields
Vaxil Bio pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-1.34
52-Week Price Change-20.00%
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)37.88
Average Volume (3m)2.06K
Important Dates
Vaxil Bio upcoming earnings date is Sep 1, 2025, TBA (Confirmed).
Last Earnings DateMay 27, 2025
Next Earnings DateSep 1, 2025
Ex-Dividend Date―
Financial Position
Vaxil Bio as a current ratio of 43.12, with Debt / Equity ratio of 0.00%
Current Ratio43.12
Quick Ratio43.12
Debt to Market Cap0.00
Net Debt to EBITDA2.52
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Vaxil Bio has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Vaxil Bio EV to EBITDA ratio is -155.24, with an EV/FCF ratio of -115.14.
EV to Sales0.00
EV to EBITDA-155.24
EV to Free Cash Flow-115.14
EV to Operating Cash Flow-115.14
Balance Sheet
Vaxil Bio has C$714.00K in cash and marketable securities with C$0.00 in debt, giving a net cash position of -C$714.00K billion.
Cash & Marketable SecuritiesC$714.00K
Total DebtC$0.00
Net Cash-C$714.00K
Net Cash Per Share-C$0.26
Tangible Book Value Per Share<C$0.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Vaxil Bio is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast72.73%